Zhejiang Shengda Pharm Net Asset Quality Index
Zhejiang Shengda Pharm net asset quality index. Zhejiang Shengda Pharm (603079) has a Net Asset Quality Index of 74.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.19 Billion minus total liabilities of CN¥561.97 Million yields net assets of CN¥1.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Zhejiang Shengda Pharm to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Zhejiang Shengda Pharm (2012–2025)
Net asset quality index of Zhejiang Shengda Pharm from 2012 to 2025. This chart shows how Zhejiang Shengda Pharm's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 74.4%, representing net assets of CN¥1.63 Billion against total assets of CN¥2.19 Billion CNY. See Zhejiang Shengda Pharm (603079) net assets for net asset value and shareholders' equity analysis.
Zhejiang Shengda Pharm Net Asset Quality Index by Year (2012–2025)
Zhejiang Shengda Pharm net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Zhejiang Shengda Pharm from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Zhejiang Shengda Pharm market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 73.4% | CN¥1.61 Billion | CN¥2.20 Billion | CN¥583.75 Million | ▲ +1.5 pp |
| 2024 | 71.9% | CN¥1.28 Billion | CN¥1.79 Billion | CN¥501.34 Million | ▼ -2.0 pp |
| 2023 | 73.9% | CN¥1.27 Billion | CN¥1.72 Billion | CN¥449.20 Million | ▼ -7.3 pp |
| 2022 | 81.2% | CN¥1.34 Billion | CN¥1.66 Billion | CN¥311.76 Million | ▲ +5.4 pp |
| 2021 | 75.8% | CN¥1.34 Billion | CN¥1.76 Billion | CN¥427.84 Million | ▼ -2.1 pp |
| 2020 | 77.9% | CN¥1.33 Billion | CN¥1.70 Billion | CN¥375.80 Million | ▲ +18.4 pp |
| 2019 | 59.5% | CN¥911.71 Million | CN¥1.53 Billion | CN¥620.88 Million | ▼ -6.6 pp |
| 2018 | 66.1% | CN¥828.42 Million | CN¥1.25 Billion | CN¥424.29 Million | ▼ -11.8 pp |
| 2017 | 78.0% | CN¥768.71 Million | CN¥985.98 Million | CN¥217.27 Million | ▲ +18.6 pp |
| 2016 | 59.4% | CN¥440.02 Million | CN¥741.37 Million | CN¥301.35 Million | ▼ -11.0 pp |
| 2015 | 70.4% | CN¥439.09 Million | CN¥624.13 Million | CN¥185.05 Million | ▲ +11.1 pp |
| 2014 | 59.3% | CN¥324.87 Million | CN¥548.27 Million | CN¥223.40 Million | ▲ +3.6 pp |
| 2013 | 55.7% | CN¥281.09 Million | CN¥505.09 Million | CN¥224.00 Million | ▲ +19.0 pp |
| 2012 | 36.7% | CN¥185.99 Million | CN¥507.42 Million | CN¥321.43 Million | — |